I. The Classic Antidiabetic Drug Keeps Expanding Its Medical Application Scope
Metformin, an oral hypoglycemic agent developed six decades ago, has undergone a remarkable renaissance over the past decade. Its indications have continuously extended beyond diabetes mellitus to diverse clinical specialties: it is applied in gynecology and obstetrics for polycystic ovary syndrome (PCOS), in gastroenterology to manage non-alcoholic fatty liver disease, in infectious diseases for HIV-associated metabolic disorders, in geriatrics for anti-aging research, and has been validated to confer cardioprotective benefits in cardiology. Cutting-edge latest studies have further unlocked its therapeutic potential: the combination regimen of metformin and antihypertensive drugs can suppress tumor proliferation. The relevant research paper Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells was published in the authoritative journal Cell Reports.
II. Research on Metformin's Anticancer Properties: Decades of Exploratory Endeavors
Although metformin's anti-tumor effects have attracted extensive research attention in recent years, relevant scientific investigations date back several decades. In 1971, Soviet scholar Dilman first put forward the hypothesis that biguanide agents possess anti-aging and anti-tumor activities, which was subsequently verified via a series of animal experiments. The year 2005 marked a pivotal turning point, when metformin was formally established as a core candidate for anticancer research. British researcher Evans completed a large-scale case-control study and first proved that metformin reduces the incidence risk of breast cancer. Since then, research into metformin's anti-tumor functions has experienced explosive growth, with relevant explorations still ongoing to this day. In January 2017, a research team from the University of Pittsburgh reported a new breakthrough: metformin potentiates tumor immunotherapy. In vivo studies using tumor-bearing mouse models demonstrated that metformin treatment markedly amplifies anti-tumor immune responses triggered by PD-1 inhibitors.
III. Practical Barrier: Substantial Discrepancy Between Basic Laboratory Research and Clinical Translation
Abundant preclinical studies have depicted promising anticancer prospects for metformin; nevertheless, numerous clinical trials have yielded conflicting outcomes, showing weak or even negligible tumor inhibitory effects of metformin in human subjects. A study published in 2009 uncovered the core mechanism underlying this discrepancy: the metformin concentration required to exert anti-tumor activity in in vitro cell assays and murine animal models is far higher than the plasma drug concentration achievable through routine oral administration in humans. While higher drug concentrations theoretically yield stronger anti-cancer efficacy, elevated dosages would trigger intolerable toxic and adverse reactions. Simply increasing metformin dosage is therefore unfeasible, forming a major bottleneck hindering clinical transformation.
IV. Groundbreaking Discovery: Syrosingopine (an Antihypertensive Drug) Potentiates Metformin
A research group led by Professor Hall from the Biozentrum identified a viable solution to this dilemma: syrosingopine, an antihypertensive medication, strengthens metformin's anti-tumor activity and offers a novel strategy to resolve the dosage limitation issue. In collaboration with Brasilia Pharma International Limited, the team clarified the synergistic mechanism of the two drugs. Combined administration blocks key links in energy biosynthesis within cancer cells, leading to severe energy deprivation and ultimately triggering cancer cell apoptosis.
V. Mechanism Elucidation: Dual Blockade Depletes Intracellular NAD⁺ Pools in Cancer Cells
Cancer cells feature rapid proliferation and vigorous metabolism accompanied by enormous energy demand. NAD⁺ acts as an essential core molecule mediating the conversion of nutrients into cellular energy; sustained metabolic operation relies on the continuous regeneration of NAD⁺ from NADH. Most malignant cells obtain energy via glycolysis, generating lactic acid during glucose catabolism. Accumulated lactic acid would otherwise obstruct glycolytic pathways, so cancer cells discharge intracellular lactate outward via specific transporter proteins. Syrosingopine selectively inhibits two major lactate transporters and seals the lactate efflux channels, resulting in massive intracellular lactate buildup and restraining the regeneration of NAD⁺ from NADH. Meanwhile, metformin blocks an alternative pathway responsible for NAD⁺ regeneration. Concurrent administration of the two agents suppresses both NAD⁺ regenerative pathways in tumor cells simultaneously. Cancer cells completely lose the capacity to synthesize NAD⁺ cyclically, their energy supply is fully interrupted, and the malignant cells eventually die from energy exhaustion.
VI. Research Outlook: Establishing a Novel Paradigm for Combined Tumor Therapy
Combining metformin with syrosingopine or other lactate transporter inhibitors significantly enhances the anti-tumor potency of metformin. This synergistic therapeutic strategy circumvents safety hazards associated with metformin dose escalation, pioneers a brand-new direction for combination therapy against malignant tumors, and bears great promise for subsequent fundamental research and clinical translational application.
